Partial
Partially Aligned
Patient Risk:
Moderate
Summary
One mechanistic claim is supported by the label, but multiple alcohol/wine-related statements present conclusions or counseling that are not supported by the provided label sections. Several claims are framed as generalizable safety guidance despite no alcohol/wine-specific labeling support in the cited sections.
Category Scores
Accurate Statements
Ezetimibe lowers cholesterol by reducing absorption of cholesterol in the intestine.
12.1 Mechanism of Action (Ezetimibe inhibits absorption of cholesterol by the small intestine).
Unsupported Statements
Whether alcohol (including wine) changes ezetimibe’s effect or increases side effects depends on factors like liver health and other medications.
The provided label sections do not describe alcohol (or wine)-specific effects or side effect modulation; only liver enzyme increases with ZETIA and drug-drug interactions are provided.
Common concerns when combining any cholesterol-lowering therapy with alcohol are medication side effects and liver-related symptoms such as unusual fatigue, abdominal pain, dark urine, or yellowing of skin/eyes.
No alcohol-combination warning language or alcohol-specific symptom list is present in the provided label sections.
The safest approach for individualized guidance about combining wine with ezetimibe is based on medical history (especially liver disease) and other drugs being taken.
The label supports liver enzyme monitoring and drug-drug interactions, but does not provide wine/alcohol-specific safety guidance.
Without interaction guidance in the provided information, alternatives to keep drinking cannot be responsibly recommended.
While the label does not include alcohol guidance, the statement moves beyond label-only observation into a prescriptive conclusion not supported by the provided sections.
The provided information does not specify ezetimibe-specific risks.
The provided label includes ezetimibe-specific risk of increased serum transaminases with guidance to test and consider withdrawal if ALT/AST ≥3×ULN persist.
Contradictions
Important Omissions
No boxed warnings, contraindications, pregnancy/lactation, pediatric use, or full adverse reaction/monitoring details are addressed in the AI claim set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The alcohol/wine counseling claims introduce label-unsupported guidance. Although not directly contradicting the label, the lack of alcohol-specific support increases the risk of misinterpretation of safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Multiple alcohol/wine-related statements are not supported by the provided FDA label sections (no alcohol/wine-specific guidance). One claim about “no ezetimibe-specific risks” conflicts with label-supported liver enzyme risk information.
Suggested Improvement
Limit statements to label-supported content from 12.1 (mechanism) and 5.2/7 (liver enzyme monitoring and listed drug-drug interactions). Frame alcohol/wine topics strictly as “not addressed in the provided label sections,” without adding effect/side-effect dependence or “safest approach” counseling.